FederalCompliance

Comparative implementation guidance

Keep what Canada learned. Anchor every U.S. rule in U.S. authority.

Canadian medical-cannabis experience supplies mature control patterns for cultivation, manufacturing, testing, security and inspection artifacts. It is evidence-informed guidance, not a substitute for FDA, DEA or state law.

The bridge

FDA's botanical-drug guidance links agricultural raw-material controls to CGMP manufacture. That makes Canada's established GACP/GMP operating knowledge directly useful when designing evidence capture, specifications, supplier qualification, batch records and inspection readiness for the U.S. pathway.

The platform stores both the comparative Canadian control and the controlling U.S. source. A crosswalk can support a design decision; it cannot create legal applicability.

Reusable control patterns

Canadian experienceU.S. implementation targetEvidence object
GACP cultivation and harvest controlsFDA botanical raw-material control plus state cultivation rulesSource lot, inputs, site, harvest and release record
GMP pharmaceutical manufactureApplicable FDA CGMP and CMC controlsMaster/batch record, specification, method and release
MMPR facility security disciplineDEA functional security standard plus state premises rulesZone map, access matrix, alarm/camera evidence and tests
Health Canada inspection artifactsDEA/FDA/state inspection readinessVersioned SOP, training, log, exception and CAPA
National framework plus provincesFederal framework plus fifty state overlaysAuthority, citation, effective date and applicability decision

Crosswalk guardrails

  • Current U.S. primary sources outrank comparative Canadian guidance.
  • State requirements remain distinct from federal registration and FDA product status.
  • Stricter controls can be adopted as internal policy without being misrepresented as law.
  • Every mapping records who approved it, when, for which site and against which source version.
  • Conflicts remain visible and route to qualified review.